ArticleJournal of biomedical materials research. Part A2024
Chitosan-nanoclay embolic material for catheter-directed arterial embolization.
Article in Journal of biomedical materials research. Part A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Therapeutic embolic agents for targeted drug delivery in transcatheter therapies: a review.Chemical communications (Cambridge, England) · 2026Review
- A multi-modal embolic gel system for long-term fluorescence imaging and photothermal therapy.Biomaterials advances · 2025Article
- Promoting Angiogenesis/Osteogenesis by a New Copper/Magnesium Hydroxide Hybrid Nanoparticle: In Vitro and In Vivo Investigation.Journal of biomedical materials research. Part A · 2025Article
- Mechanical investigation of a Tandem embolization-visualization system for minimally invasive procedures.Journal of the mechanical behavior of biomedical materials · 2024Article
- An Investigation on the Effect of Contrast Agents in the Chitosan-Nanoclay Shear Thinning Hydrogel for Trans-Catheter Arterial Embolization.JOM (Warrendale, Pa. : 1989) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Minimally invasive transcatheter embolization is a common nonsurgical procedure in interventional radiology. It is used for the deliberate occlusion of blood vessels for the treatment of disease or injured vasculature, including vascular malformation and malignant/benign tumors. Here, we introduce a gel embolic agent comprising chitosan nanofibers and nanoclay with excellent catheter injectability and tunable mechanical properties for embolization. The properties of the gel were optimized by varying the ratio between each individual component and also adjusting the total solid content. The rheological studies confirm the shear thinning property and gel nature of the developed gel as well as their recoverability. Injection force was measured to record the force required to pass the embolic gel through a clinically relevant catheter, evaluating for practicality of hand-injection. Theoretical predicted injection force was calculated to reduce the development time and to enhance the physician's experience. The stability of occlusion was also tested in vitro by monitoring the pressure required to displace the gel. The engineered gels exhibited sterility, hemocompatibility and cell biocompatibility, highlighting their potential for transcatheter embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.